NO20072065L - Substituerte piperidin-CCR2-antagonister - Google Patents

Substituerte piperidin-CCR2-antagonister

Info

Publication number: NO20072065L
Authority: NO; Norway
Prior art keywords: substituted piperidine; ccr2 antagonists; ccr2; antagonists; substituted
Prior art date: 2004-09-28

Application number

NO20072065A

Other languages

English (en)

Norwegian (no)

Inventor

Meng Pan

Michael P Wachter

Mingde Xia

Duane E Demong

Scott R Pollack

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-28

Filing date

2007-04-23

Publication date

2007-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35788241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072065(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-04-23 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2007-06-15 Publication of NO20072065L publication Critical patent/NO20072065L/no

Links

102100031151 C-C chemokine receptor type 2 Human genes 0.000 title abstract 3
101710149815 C-C chemokine receptor type 2 Proteins 0.000 title abstract 3
239000005557 antagonist Substances 0.000 title abstract 2
150000003053 piperidines Chemical class 0.000 title 1
NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
239000002207 metabolite Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Immunology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Obesity (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)

NO20072065A 2004-09-28 2007-04-23 Substituerte piperidin-CCR2-antagonister NO20072065L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US61392204P	2004-09-28	2004-09-28
PCT/US2005/032500 WO2006036527A1 (en)	2004-09-28	2005-09-12	Substituted dipiperdine ccr2 antagonists

Publications (1)

Publication Number	Publication Date
NO20072065L true NO20072065L (no)	2007-06-15

Family

ID=35788241

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20072065A NO20072065L (no)	2004-09-28	2007-04-23	Substituerte piperidin-CCR2-antagonister

Country Status (18)

Country	Link
US (1)	US20060069123A1 (es)
EP (1)	EP1802602A1 (es)
JP (1)	JP2008514700A (es)
KR (1)	KR20070063562A (es)
CN (1)	CN101065374A (es)
AR (1)	AR053413A1 (es)
AU (1)	AU2005290028A1 (es)
BR (1)	BRPI0516166A (es)
CA (1)	CA2582225A1 (es)
CR (1)	CR9088A (es)
EA (1)	EA200700757A1 (es)
EC (1)	ECSP077358A (es)
IL (1)	IL182254A0 (es)
MX (1)	MX2007003793A (es)
NO (1)	NO20072065L (es)
TW (1)	TW200621707A (es)
WO (1)	WO2006036527A1 (es)
ZA (1)	ZA200702544B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007130712A1 (en) *	2006-01-31	2007-11-15	Janssen Pharmaceutica, Nv	Substituted dipiperidine as ccr2 antagonists for the treatment of inflammatory diseases
WO2007106797A2 (en) *	2006-03-14	2007-09-20	Janssen Pharmaceutica, Nv	A method of use for substituted dipiperidine ccr2 antagonists
US7687508B2 (en) *	2006-07-28	2010-03-30	Bristol-Myers Squibb Company	Cyclic derivatives as modulators of chemokine receptor activity
US7629351B2 (en) *	2006-07-28	2009-12-08	Bristol-Myers Squibb Company	N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
US7671062B2 (en) *	2006-07-28	2010-03-02	Bristol-Myers Squibb Company	Modulators of chemokine receptor activity, crystalline forms and process
US20080076120A1 (en) *	2006-09-14	2008-03-27	Millennium Pharmaceuticals, Inc.	Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
PT2530083T (pt)	2006-09-22	2016-08-01	Pharmacyclics Llc	Inibidores de tirosina cinase de bruton
WO2008109238A1 (en) *	2007-03-02	2008-09-12	Janssen Pharmaceutica N.V.	Substituted cyclopentyl piperidine ccr2 antagonists
US20120101113A1 (en)	2007-03-28	2012-04-26	Pharmacyclics, Inc.	Inhibitors of bruton's tyrosine kinase
CA2874756C (en) *	2007-03-28	2018-05-29	Pharmacyclics, Inc.	Inhibitors of bruton's tyrosine kinase
TW200904423A (en) *	2007-06-20	2009-02-01	Glaxo Group Ltd	Spiroindolines as modulators of chemokine receptors
WO2009061881A1 (en) *	2007-11-07	2009-05-14	Glaxo Group Limited	Spirodihydrobenzofurans as modulators of chemokine receptors
WO2009076404A1 (en) *	2007-12-10	2009-06-18	Epix Delaware, Inc.	Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
CA2708364A1 (en)	2007-12-11	2009-06-18	Efrat Ben-Zeev	Carboxamide compounds and their use as chemokine receptor agonists
JP5530430B2 (ja) *	2008-06-23	2014-06-25	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｃｃｒ２のピペリジルアクリルアミドアンタゴニスト
US20110224235A1 (en)	2008-07-16	2011-09-15	Pharmacyclics, Inc.	Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2010068663A1 (en) *	2008-12-10	2010-06-17	Janssen Pharmaceutica Nv	4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
CA2758918A1 (en) *	2009-04-16	2010-10-21	Janssen Pharmaceutica Nv	4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2
JP5675773B2 (ja) *	2009-04-17	2015-02-25	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎＰｈａｒｍａｃｅｕｔｉｃａＮａａｍｌｏｚｅＶｅｎｎｏｏｔｓｃｈａｐ	Ｃｃｒ２の４−アゼチジニル−１−フェニル−シクロヘキサンアンタゴニスト
KR20120006051A (ko) *	2009-04-17	2012-01-17	얀센 파마슈티카 엔.브이.	Ｃｃｒ2의 4-아제티디닐-1-헤테로원자 연결된 사이클로헥산 길항제
KR101151415B1 (ko)	2009-07-10	2012-06-01	양지화학 주식회사	Ｃｃｒ２ 길항제로서의 피페라지닐에틸 3-아미노피롤리딘 유도체
US8383812B2 (en)	2009-10-13	2013-02-26	Bristol-Myers Squibb Company	N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
MX342405B (es)	2010-06-03	2016-09-28	Pharmacyclics Inc	El uso de inhibidores de la tirosina quinasa de bruton (btk).
WO2011159854A1 (en)	2010-06-17	2011-12-22	Janssen Pharmaceutica Nv	Cyclohexyl-azetidinyl antagonists of ccr2
TW201204733A (en) *	2010-06-25	2012-02-01	Kowa Co	Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
KR20130121891A (ko) *	2010-12-01	2013-11-06	얀센 파마슈티카 엔.브이.	Ｃｃｒ２의 4-치환된-사이클로헥실아미노-4-피페리디닐-아세트아미드길항제
CA2841080A1 (en)	2011-07-13	2013-01-17	Pharmacyclics, Inc.	Inhibitors of bruton's tyrosine kinase
CA2852160A1 (en)	2011-10-28	2013-05-02	Galderma Research & Development	New leukocyte infiltrate markers for rosacea and uses thereof
US8377946B1 (en)	2011-12-30	2013-02-19	Pharmacyclics, Inc.	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CN102603611B (zh) *	2012-01-11	2014-05-07	巨化集团公司	一种三氟甲基代哌啶类化合物的制备方法
CN107050020A (zh)	2012-05-01	2017-08-18	特兰斯拉图姆医学公司	用于治疗和诊断致盲性眼病的方法
CA2875986C (en)	2012-06-04	2020-06-09	Pharmacyclics, Inc.	Crystalline forms of a bruton's tyrosine kinase inhibitor
AR091516A1 (es) *	2012-06-22	2015-02-11	Actelion Pharmaceuticals Ltd	Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
EP2877598A1 (en)	2012-07-24	2015-06-03	Pharmacyclics, Inc.	Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
EP2920180A4 (en)	2012-11-15	2016-04-13	Pharmacyclics Inc	PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS
WO2015017812A1 (en)	2013-08-02	2015-02-05	Pharmacyclics, Inc.	Methods for the treatment of solid tumors
JP6429292B2 (ja)	2013-08-12	2018-11-28	ファーマサイクリックスエルエルシー	Ｈｅｒ２増幅性癌の処置のための方法
CR20160203A (es)	2013-09-30	2016-08-31	Pharmacyclics Llc	Inhibidores de tirosina cinasa de bruton
US9962251B2 (en)	2013-10-17	2018-05-08	Boston Scientific Scimed, Inc.	Devices and methods for delivering implants
CA2942528A1 (en)	2014-03-20	2015-09-24	Pharmacyclics Inc.	Phospholipase c gamma 2 and resistance associated mutations
CA2959602A1 (en)	2014-08-01	2016-02-04	Pharmacyclics Llc	Inhibitors of bruton's tyrosine kinase
CN106573002A (zh)	2014-08-07	2017-04-19	药品循环有限责任公司	布鲁顿氏酪氨酸激酶抑制剂的新型制剂
DK3050574T3 (da)	2015-01-28	2020-01-20	Univ Bordeaux	Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
IL315294A (en)	2015-03-03	2024-10-01	Pharmacyclics Llc	Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
AU2019252676A1 (en)	2018-04-11	2020-11-26	Ohio State Innovation Foundation	Methods and compositions for sustained release microparticles for ocular drug delivery
WO2020048831A1 (en)	2018-09-03	2020-03-12	Bayer Aktiengesellschaft	5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048828A1 (en)	2018-09-03	2020-03-12	Bayer Pharma Aktiengesellschaft	5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048830A1 (en)	2018-09-03	2020-03-12	Bayer Aktiengesellschaft	5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9803228D0 (en) *	1998-02-17	1998-04-08	Zeneca Ltd	Chemical compounds
GB0107907D0 (en) *	2001-03-29	2001-05-23	Smithkline Beecham Plc	Novel compounds

2005
- 2005-09-12 BR BRPI0516166-5A patent/BRPI0516166A/pt not_active IP Right Cessation
- 2005-09-12 CN CNA2005800403016A patent/CN101065374A/zh active Pending
- 2005-09-12 EP EP05797411A patent/EP1802602A1/en not_active Withdrawn
- 2005-09-12 CA CA002582225A patent/CA2582225A1/en not_active Abandoned
- 2005-09-12 JP JP2007534623A patent/JP2008514700A/ja active Pending
- 2005-09-12 MX MX2007003793A patent/MX2007003793A/es unknown
- 2005-09-12 AU AU2005290028A patent/AU2005290028A1/en not_active Abandoned
- 2005-09-12 US US11/224,215 patent/US20060069123A1/en not_active Abandoned
- 2005-09-12 KR KR1020077009314A patent/KR20070063562A/ko not_active Withdrawn
- 2005-09-12 EA EA200700757A patent/EA200700757A1/ru unknown
- 2005-09-12 WO PCT/US2005/032500 patent/WO2006036527A1/en not_active Ceased
- 2005-09-27 TW TW094133431A patent/TW200621707A/zh unknown
- 2005-09-27 AR ARP050104063A patent/AR053413A1/es not_active Application Discontinuation
2007
- 2007-03-27 ZA ZA200702544A patent/ZA200702544B/xx unknown
- 2007-03-27 IL IL182254A patent/IL182254A0/en unknown
- 2007-03-28 EC EC2007007358A patent/ECSP077358A/es unknown
- 2007-04-23 NO NO20072065A patent/NO20072065L/no not_active Application Discontinuation
- 2007-04-27 CR CR9088A patent/CR9088A/es unknown

Also Published As

Publication number	Publication date
JP2008514700A (ja)	2008-05-08
KR20070063562A (ko)	2007-06-19
EA200700757A1 (ru)	2007-10-26
MX2007003793A (es)	2007-07-11
TW200621707A (en)	2006-07-01
WO2006036527A1 (en)	2006-04-06
IL182254A0 (en)	2007-09-20
ECSP077358A (es)	2007-04-26
AU2005290028A1 (en)	2006-04-06
EP1802602A1 (en)	2007-07-04
AR053413A1 (es)	2007-05-09
US20060069123A1 (en)	2006-03-30
ZA200702544B (en)	2008-09-25
CA2582225A1 (en)	2006-04-06
CN101065374A (zh)	2007-10-31
BRPI0516166A (pt)	2008-08-26
CR9088A (es)	2008-09-09

Legal Events

Date	Code	Title	Description
2010-04-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20072065L (no)	2007-06-15	Substituerte piperidin-CCR2-antagonister
NO20070387L (no)	2007-03-20	Kvarternaere salt-CCR2-antagonister
NO20065868L (no)	2007-02-16	Substituerte aryl- og heteroarylderivater som metabolisme- og profylkasemodulatorer og behandling av forstyrrelser forbundet med dette
NO20054206L (no)	2005-10-19	Bifenylderivater
NO20083567L (no)	2008-10-16	Hydantoinderivater for behandling av inflammatoriske forstyrrelser
NO20084129L (no)	2008-10-29	Pyridin(3,4-B)Pyrazinoner
NO20092374L (no)	2009-09-15	Forbindelser som har bade angiotensin II receptorantagonisme og PPARy aktiverende aktiviteter
WO2005121130A3 (en)	2006-07-20	Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
DK1971601T3 (da)	2010-02-08	N4-phenyl-quinazolin-4-aminderivater og beslægtede forbindelser som ERBB Type 1-receptortyrosinkinase-inhibitorer til behandling af hyperproliferative sygdomme
NO20064065L (no)	2006-11-28	Diaminopyrimidiner som P2X3 og P2X2/3 antagonister
NO20073663L (no)	2007-09-03	Tiazol-4-karboksamid-derivater som mGluR5 antagonister
NO20061454L (no)	2006-07-06	Compounds having CRTH2 antagonist activity
NO20075624L (no)	2007-11-28	Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
NO20080675L (no)	2008-03-13	P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20080061L (no)	2008-04-07	Imidazolyl-pyrimidinforbindelser for anvendelse til behandling av proliferative lidelser
NO20080187L (no)	2008-03-14	Aspartylproteaseinhibitorer
NO20074509L (no)	2007-11-12	Kombinasjon av organiske forbindelser
NO20084583L (no)	2008-12-04	Makrosykliske kinase-inhibitorer
NO20080445L (no)	2008-01-23	Nye azetidinderivater som neurokininreseptorantagonister for behandling av gastrointestinale sykdommer
TW200616620A (en)	2006-06-01	Compounds for the treatment of inflammatory disorders
NO20074583L (no)	2007-10-12	Substiverte bis aryl- og heteroarylforbindelser som selektive 5HT2A antaconister
NO20071593L (no)	2007-05-22	Pyrimidinderivater
NO20080761L (no)	2008-06-03	Acykliske Ikur inhibitorer
NO20063501L (no)	2006-09-28	Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres syntese
NO20091741L (no)	2009-05-29	Pyrazolinforbindelser som mineralkortikoidreceptorantagonister